Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamsulosin/Solifenacin Combination Therapy for Benign Prostate Hyperplasia
NCT02827578Phase 3Unknown
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Jan 2016
- Primary completion
- Aug 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Tamsulosin + Solifenacin with Tamsulosin + Solifenacin Placebo (2 arms). Primary endpoints: The change of Total Urgency and Frequency Score/24h at 12 weeks and The change of total International prostate symptom score at 12 weeks. Status: unknown.
02
Drugs
solifenacin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02827578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02827578.